Saving Heart Muscle After a Heart Attack: Nature Reports PeriFlow's First-in-Class Capillary-Selective Vasodilator

Trial StartCLN-2501Positive

AI Analysis

Summary

PeriFlow Therapeutics is advancing CLN-2501, a first-in-class capillary-selective vasodilator designed to restore blood flow after acute myocardial infarction by targeting capillary no-reflow. The program is moving toward clinical development in the US.

Importance:4/10

Sentiment:

0.60

first-in-classcardiovascularcapillary-selective vasodilatorclinical developmentmechanism of action

Related Companies

$TRAX

Read the original article

Published by PR Newswire Biotech on October 14, 2026 5:30 PM

Read Original